ADVANCES IN RADIOTHERAPY IN THE GYNECOLOGIC MALIGNANCIES

被引:3
作者
DEMBO, AJ
BALOGH, JM
机构
[1] Division of Radiation Oncology, Toronto-Bayview Regional Cancer Centre
[2] Departments of Radiology, and Obstetrics and Gynecology, University of Toronto
来源
SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 06期
关键词
brachytherapy; chemoradiotherapy; radiation fractionation;
D O I
10.1002/ssu.2980060606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We review, for their wider applicability, four advances in the radiotherapeutic management of the gynecologic malignancies. Attempts at improving upon results obtained with radiotherapy by the addition of chemotherapy have usually followed one of two temporal strategies: Sequential chemotherapy‐radiotherapy (so‐called neo‐adjuvant chemotherapy), or chemotherapy given concurrently with radiotherapy. The pros and cons of both models are discussed. Recent work suggests that there is a differential response between the acutely reacting normal tissues, as well as tumor, and the late‐reacting normal tissues, which is dependent upon the radiation fraction size. The rationale and some important clinical applications are reviewed. Advances in brachytherapy include the high dose rate treatment and the use of rigid templates to guide the accurate placement of the interstitial implant. The controversies surrounding these approaches require further study before the precise place of these techniques is known. Finally, in vulvar cancer, the addition of radiotherapy to surgery is being studied to permit less radical operations in early disease, and greater local tumor control in advanced disease. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:323 / 327
页数:5
相关论文
共 34 条
[1]  
Friedlander M, Kaye SB, Sullivan A, Et al., Cervical Carcinoma: A drug‐responsive tumor—Experience with combined cisplatin, vinblastine and bleomycin therapy, Gynecologic Oncology, 16, pp. 275-281, (1983)
[2]  
Sardi JE, DiPaolo GR, Giaroli A, Et al., Results of a phase II trial with neoadjuvant chemotherapy in carcinoma of the cervix uteri, Gynecologic Oncology, 31, pp. 256-261, (1988)
[3]  
Buxton EJ, Meanwell CA, Hilton C, Et al., Combination bleomycin, ifosfamide and cisplatin chemotherapy in cervical cancer, J Nat Cancer Inst, 81, pp. 359-361, (1989)
[4]  
Kavanagh JJ, Delclos L, Wallace S, Arterial chemotherapy prior to radiotherapy in advanced gynecologic cancer, Gynecologic Cancer Diagnosis and Treatment Strategies, pp. 281-284, (1987)
[5]  
Withers HR, Taylor JMG, Maciejewski B, The hazard of accelerated tumor clonogen repopulation during radiotherapy, Acta Oncologica, 27, pp. 98-113, (1988)
[6]  
Tannock IF
[7]  
Tannock IF, Chemotherapy in conjunction with radiotherapy and/ or surgery in head and neck cancer, Oxford Textbook of Oncology
[8]  
Chauvergne J, Rohart J, Heron JF, Et al., Randomized phase III trial of neo‐adjuvant chemotherapy (CT) and radiotherapy (RT) vs RT in stage 11B, III carcinoma of cervix: A cooperative study of the french oncology centers, Proc ASCO, 7, (1988)
[9]  
Haie C, Pejovic MH, Chassagne D, Et al., Feasibility study of an alternating schedule of radiotherapy and chemotherapy in advanced uterine cervical carcinoma, Radiotherapy Oncol, 12, pp. 121-127, (1988)
[10]  
Piver MS, Barlow JJ, Vongtama V, Hydroxyurea: A radiation potentiator in carcinoma of the uterine cervix, Am J Obstet Gynecol, 147, pp. 803-808, (1983)